XJPX
4272
Market cap1.99bUSD
Oct 09, Last price
2,118.00JPY
1D
0.21%
1Q
6.83%
Jan 2017
46.78%
Name
Nippon Kayaku Co Ltd
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Nippon Kayaku Co., Ltd., along with its subsidiary companies, is a global enterprise based in Tokyo, Japan. Established in 1916 and originally known as Nihon Kayaku Seizou Co., Ltd. until its rebranding in 1945, the company specializes in the development, manufacturing, and sale of a diverse range of products across several key sectors. Its Functional and Chemical Business segment supplies advanced materials, including epoxy and UV-curable resins, sealants for LCD and LED screens, maleimide resins, photoresists, and insulating materials crucial for micro-electromechanical systems (MEMS), as well as various cleaning agents. This division also produces a variety of colorants, such as inkjet pigments, textile and paper dyes, and materials used in thermal paper. Furthermore, it manufactures catalysts for acrylic and methacrylic acid production, alongside optical and analytical components like polarizing films, inorganic polarizers, parts for liquid crystal displays and projectors, and components for X-ray analysis. The Pharmaceuticals Business segment focuses on healthcare, offering a portfolio that includes anti-cancer and cancer-related medications, biosimilars, generic drugs, interventional radiology products, and cardiovascular treatments. It also provides bulk pharmaceuticals, drug intermediates, and cancer diagnostic agents, notably featuring GlycoMark, a specialized marker for managing blood sugar levels in diabetes. In the Safety Systems Business segment, the company develops and produces critical automotive safety components, such as airbag inflators, micro gas generators for seatbelt pretensioners, and squibs. Finally, the Agrochemicals Business segment provides solutions for agricultural and public health needs, encompassing agricultural insecticides, herbicides, soil fumigants, and products designed for insanitary pest control. Beyond these core industrial activities, Nippon Kayaku Co., Ltd. also manages real estate leasing services.
Key people
Yoshiki Akatani
Managing Executive Officer · since 2025
Takumi Fujita
Managing Executive Officer, Director of Safety System Business · since 2025
Shinji Inoue
Managing Executive Officer, Director · since 2024
Masako Aono
Senior Executive Officer · since 2025
Tsutomu Kawamura
Senior Executive Officer, Director of Accounting · since 2025
Shinya Ikeda
Executive Officer, Chief Director of Sales in Pharmaceutical Regional Business Unit in Life Sciences Business · since 2024
Atsurou Inubushi
Executive Officer, Chief Director of API, International and Diagnostics in Life Science Business Area Pharmaceutical Unit · since 2023
Kazuhiko Ishii
Executive Officer, Director of Fine Chemical Research Center in Fine Chemicals Business · since 2024
Shigehide Kagaya
Executive Officer, Director of Fine Chemicals Business Area Catalyst Business · since 2024
Yoshinori Kato
Executive Officer, Director of Technology Management Environmental Safety Promotion · since 2023
Tadayuki Kiyoyanagi
Executive Officer, Manager of Tokyo Plant · since 2023
Shuichi Kobayashi
Executive Officer, Manager of Fukuyama Plant in Fine Chemicals Business Area · since 2024
Seiichiro Kodama
Executive Officer, Director of Agro Research Institute in Agro Unit in Life Science Business Area, Manager of Biological Group · since 2023
Ichio Kohinata
Executive Officer, Director of Legal Affairs · since 2025
Tsuyoshi Kuboyama
Executive Officer, Chief Director of Business Development in Area Pharmaceutical Business in Life Science Business · since 2024
Shigeru Maeda
Executive Officer, Director of Mobility & Imaging Business Area Planning · since 2024
Yasushi Matsumura
Executive Officer · since 2025
Akihiko Miura
Executive Officer, Senior Director of Technology and RC Supervision Technology · since 2025
Yuko Nagai
Executive Officer, Chief Director of Reliability Assurance in Life Science Business Area Pharmaceutical Business · since 2023
Atsuya Saimoto
Executive Officer, Chief Director of API International Diagnostic in Life Sciences Business Area Pharmaceuticals Unit · since 2024
Valuation
Title JPY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026‑03 | 2025‑03 | 2024‑03 | 2023‑03 | 2022‑03 | 2021‑03 | 2020‑03 | 2019‑03 | 2018‑03 | 2017‑03 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||